Question 1

How much weight loss is expected with Tirzepatide 15 mg?

Accepted Answer

In the SURMOUNT-1 trial (New England Journal of Medicine, 2022; N = 2,539 adults with obesity without T2D), mean weight loss at 72 weeks was 22.5% (about 23.6 kg) with Tirzepatide 15 mg, 19.5% with 10 mg and 15.0% with 5 mg — versus 3.1% for placebo. That is the magnitude described in the literature; individual results vary with adherence, diet and physical activity.

Question 2

Is Tirzepatide more effective than Semaglutide?

Accepted Answer

In the SURPASS-2 trial (Lancet, 2021; T2D, 40 weeks), Tirzepatide 15 mg reduced HbA1c by 2.30% versus 1.86% for Semaglutide 1 mg — a statistically significant difference. In the direct head-to-head SURMOUNT-5 (2024, obesity without T2D), Tirzepatide 15 mg showed superior weight loss to Semaglutide 2.4 mg. The literature converges that Tirzepatide has larger effect magnitude, but individual clinical decisions consider tolerance, comorbidities, contraindications and availability.

Question 3

How is Tirzepatide titration described in the literature?

Accepted Answer

The SURMOUNT-1 trial schedule and FDA label start at 2.5 mg weekly × 4 weeks (starter dose, not therapeutic), increasing by 2.5 mg every 4 weeks up to the maintenance dose chosen by the physician (5 · 7.5 · 10 · 12.5 or 15 mg). Slow titration reduces gastrointestinal effects. The calculator generates the theoretical schedule automatically for the selected target dose.

Question 4

How do Mounjaro/Zepbound auto-injector pens work?

Accepted Answer

The 6 strengths (2.5/5/7.5/10/12.5/15 mg) come in Lilly single-dose auto-injector pens (Mounjaro KwikPen outside the US, Zepbound in the US). Each pen delivers 0.5 mL as a single subcutaneous injection (abdomen, thigh or upper arm) — unlike Wegovy/Ozempic pens from Novo, which count clicks and have variable volumes. Concentration varies by strength: 2.5 mg pen = 5 mg/mL; 15 mg pen = 30 mg/mL.

Question 5

How much does Tirzepatide cost per month?

Accepted Answer

Reference average prices (out-of-pocket, vary by pharmacy and country): Brazil R$ 1,400 to R$ 1,850/month (4 pens); US about US$ 1,050 to US$ 1,200/month (Zepbound); Europe € 330 to € 460/month. The calculator shows the estimated amount for the selected dose and currency. Insurance coverage varies widely — check with your carrier.

Question 6

Who should NOT use Tirzepatide?

Accepted Answer

The label contraindicates Tirzepatide in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2), and in those with known hypersensitivity to the drug. Caution with previous pancreatitis, gallbladder disease, gastroparesis, untreated proliferative diabetic retinopathy, pregnancy and breastfeeding. Any decision to start or discontinue requires medical evaluation.

Question 7

Does this calculator prescribe Tirzepatide?

Accepted Answer

No. It is a strictly educational tool to visualize data from the SURMOUNT-1 and SURPASS-2 trials applied to different doses. It does not replace prescription, titration, adverse-event monitoring or individualized clinical assessment. Official labels (FDA/EMA/ANVISA) are the primary therapeutic reference.

Week	Dose
1–4	2.5 mg
5–8	5 mg
9–12	7.5 mg
13–16	10 mg
17+	10 mg

Educational Tirzepatide (Mounjaro®) Calculator

About the auto-injector pen

Clinical projection (SURMOUNT-1, 72 weeks)

Titration described in the literature

Scientific references

Absolute contraindications

Essential notice